Study S003230

Safety, Tolerability and Pharmacokinetics of NNC0487-0111 in Participants With Overweight or Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05369390
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 144
Start: 2022-05-11
Primary completion: 2024-01-09
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity
Interventions: DRUG:NNC0487-0111 A; DRUG:NNC0487-0111 B; OTHER:Placebo B (NNC0487-0111 B); OTHER:Placebo A (NNC0487-0111 A)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1270-0852

Registered primary outcomes

Number of treatment emergent adverse events (TEAE) [Part A: From pre-dose on Day 1 to 22 days; Part B: From pre-dose on Day 1 to 31 days; Part C and D: From pre-dose on Day 1 to 105 days]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011082	Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. Gasiorek A, Lancet (London, England)	2025	Randomized trial	PMID 40550229 DOI	cites ClinicalTrials.gov:NCT05369390; registry reference DERIVED:40550229